RxDoctor Payments Data

James Lee, DO

Family Medicine · Woodstock, GANPI 1790715621

Payments from drug & device makers

$11,273in general payments, 2019–2025

Across 692 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Sanofi-aventis U.S. LLC$1K
  • Lilly USA, LLC$948
  • AbbVie$896
  • Amgen$434
  • plus $4K from 41 others

What the payments were for

  • Speaking & faculty fees$350%
  • Food & beverage$11,11999%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,273 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$180,543
Medicare patients
329
Services billed
3,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$44,177
JardianceEmpagliflozin20$34,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$29,467
FarxigaDapagliflozin Propanediol22$27,901
XareltoRivaroxaban19$23,863
ArexvyRsvpref3 Antigen/As01e/Pf68$21,640
Soliqua 100-33Insulin Glargine/Lixisenatide19$16,921
EliquisApixaban14$9,161
Liothyronine Sodium72$2,646
Omega-3 Acid Ethyl Esters29$1,931
Pantoprazole Sodium135$1,857
Rosuvastatin Calcium191$1,836
Fenofibrate88$1,625
Atorvastatin Calcium202$1,483
Levothyroxine Sodium170$1,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arexvy$304$51,10787 claims
Novo NordiskOzempic$2,069$44,17727 claims
Boehringer IngelheimJardiance$197$34,26220 claims
AstraZenecaFarxiga$1,370$27,90122 claims
Johnson & JohnsonXarelto$136$23,86319 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,191$16,92119 claims
PfizerEliquis$291$9,16114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Woodstock

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →